Blueberry in the news again!

Blueberry's CEO John Ridden was interviewed by Times writer Michael Cape. John and Michael spoke about how Blueberry benefitted from AstraZeneca's move to Cambridge, which led to husband and wife team David and Julie [...]

2018-02-13T12:31:32+00:00 March 16th, 2017|

Blueberry CSO presents at Superbugs & Superdrugs conference

CSO David Cook presents at the “Superbugs & Supderdrugs” conference held in Iselin, USA. The conference brought together experts in anti-microbial drug resistance from Government, Pharma and Biotech. David gave a presentation on “Targeting Mechanisms [...]

2017-02-16T10:30:04+00:00 November 14th, 2016|

HRH Duke of York visits Blueberry’s laboratories

Blueberry was delighted to host HRH the Duke of York on Tuesday the 2nd of February when he visited our laboratories during a visit to Alderley Park as part of the “Pitch@Palace 5.0 tour (”. [...]

2018-02-13T12:31:35+00:00 February 2nd, 2016|

Blueberry Therapeutics Ltd joins the BEAM Alliance

  Blueberry Therapeutics Ltd is delighted to have joined the BEAM Alliance (Biopharmaceutical companies from Europe in Anti-Microbial resistance). The BEAM Alliance aims to raise awareness on the very specific issues that small and medium European [...]

2016-01-22T14:44:47+00:00 December 1st, 2015|

Blueberry win NHS SBRI contract

Blueberry Therapeutics are delighted to have won an SBRI NHS contract to progress their smart wound dressing technology through Feasibility studies. The contract will allow Blueberry to complete preclinical feasibility studies of a hydrogel based [...]

2018-02-13T12:31:35+00:00 May 13th, 2015|

Blueberry will be at Biotrinity 2015

Both Dr John Ridden (CEO) and Dr Mike Davies (CMO) will be at Biotrinity from the 11th May through until 13th May. We are very much looking forward to meeting with old friends, colleagues, investors [...]

2018-02-13T12:31:35+00:00 May 8th, 2015|

Blueberry raises $1.75M in investment

Blueberry today announced the successful completion of an investment round raising a total of $1.75M from both UK and Swiss based investors. The investment will help take its 2 most advanced programs through to regulatory [...]

2018-02-13T12:31:35+00:00 April 8th, 2015|

Blueberry launch new website

Blueberry Therapeutics today announced the launch of their new web site. John Ridden CEO and co-founder described the new site as a 'fresh clean communication route through which we can reach out to patients, collaborators [...]

2018-02-13T12:31:35+00:00 April 3rd, 2015|